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Previewsestablish a linkbetween this keyenzyme in
the eicosanoid pathway and the suscepti-
bility of humans to two diverse mycobac-
terial diseases.
The precise mechanism by which
these effects are mediated remains
obscure. In the zebrafish, mutation of
lta4h results in hypersusceptibility to M.
marinum, presumably because LTA4 can
no longer be converted to the proinflam-
matory eicosanoid LTB4 and is instead
shunted to form the anti-inflammatory
eicosanoid LXA4. In this scenario, the
inflammatory balance is shifted too far
toward an anti-inflammatory state (Fig-
ure 1). In marked contrast, LTA4H poly-
morphisms in humans are strongly asso-
ciated with protection from diseases
caused byM. tuberculosis andM. leprae.
SNPs in the LTA4H locus have previously
been reported and there was found to be
a positive correlation between LTA4H
polymorphism and the amount of LTB4
produced in vitro by granulocytes from
the affected individuals (Helgadottir
et al., 2006). If the heterozygosity at
LTA4H described by Tobin and col-
leagues is also associated with increased
LTB4 production in vivo resulting inenhanced protection from TB or leprosy,
this contravenes the conclusions from
the zebrafish model where lta4h muta-
tions are hypothesized to cause lower
LTB4 levels. Measurement of LTB4 and
LXA4 concentrations in sera from the
human subjects and in the mutant zebra-
fish infected with M. marinum certainly
would help clarify this issue. Nonetheless,
this report highlights two features of
LTA4H in mycobacterial diseases: (1)
Perturbations of the eicosanoid axis in
animal models as well as humans can
affect the outcome of mycobacterial
infections, and (2) the interplay between
proinflammatory leukotrienes and anti-
inflammatory lipoxins is complex. Addi-
tional studies clearly are warranted to
more fully elucidate the roles of eicosa-
noids in mediating the optimal balance
between proinflammatory and anti-
inflammatory effects for a given myco-
bacterial infection (Figure 1).REFERENCES
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Productive transcription of the HIV-1 genome involves RNA polymerase II working in concert with the viral
protein Tat and its team of cofactors in a highly orchestrated process. Now, Pagans and colleagues report
that the lysine methyltransferase Set7/9-KMT7 associates with Tat to stimulate RNA polymerase II elongation
of the integrated provirus. Set7/9-KMT7 also methylates Tat, and this enhances Tat function.A defining step in the replication cycle
of HIV-1 and all retroviruses is reverse
transcription of the viral genomic RNA
into cDNA and integration of the proviral
genome into a host cell chromosome.
After integration, RNA polymerase II
(RNAP II) is recruited to the promoter
located in the 50 long terminal repeat
(LTR) sequences of the provirus, and the
viral genome is transcribed back intoRNA. Spliced RNA serves as viral
mRNA, and unspliced RNA serves as
mRNA or is packaged into viral particles
that assemble at the plasma membrane.
Mechanisms involved in RNAP II tran-
scription of the HIV-1 provirus have
been actively studied, both because of
their general interest and because this
essential step in the viral life cycle has
the potential to be targeted by antiviraldrugs. It has become clear in recent
years that productive transcription of
the HIV-1 genome involves RNAP II
working in concert with a viral protein
known as Tat and its team of cofactors
in a highly orchestrated process. A publi-
cation from Pagans and colleagues
(Pagans et al., 2010) in this issue of Cell
Host & Microbe identifies a new team-
mate of Tat that functions in an early7, March 18, 2010 ª2010 Elsevier Inc. 179
Figure 1. Covalent Modifications of HIV-1 Tat Protein Control Transactivation Function
The indicated cis-regulatory elements in the HIV-1 50 LTR direct RNAP II to the viral promoter. The
Tat:Set7/9-KMT7:Cyclin T1:CDK9 complex binds to the TAR RNA element at the 50 end of the nascent
HIV-1 transcript. CDK9 is then able to phosphorylate substrates in the RNAP II complex, including the
RNAP II carboxy-terminal domain (CTD), and this stimulates transcriptional elongation. Covalent modifi-
cations of Tat shown in green by Set7/9-KMT7 (monomethylation, Me), Hdm2 (ubiquitylation, Ub), and
HATs (acetylation, Ac) positively regulate Tat function. Covalent modifications of Tat shown in red by
PRMT6 and SETDB1/2 (methylation, Me) negatively regulate Tat function. A nucleosome (Nuc-1) that
assembles downstream of the transcriptional start site is shown.
Cell Host & Microbe
Previewsstep in this increasingly complex story of
Tat transactivation.
The basal level of RNAP II transcription
of the HIV-1 provirus is low due to the
action of two negative factors, NELF and
DSIF, which associate with RNAP II and
limit transcriptional elongation. At some
point, RNAP II is able to transcribe the
entire proviral genome, and the transcript
is spliced into an mRNA that encodes the
viral Tat protein. Tat then functions in
a positive-feedback loop to strongly acti-
vate RNAP II elongation—the magnitude
of activation in experimental systems
can be greater than 100-fold. Tat is re-
quired for HIV-1 replication in tissue
culture and is therefore thought to be
essential for viral pathogenesis in infected
individuals.
A critical mechanism involved in Tat
transactivation was worked out a decade
ago when Tat was found to bind directly
to a general RNAP II elongation factor
termed P-TEFb (Peterlin and Price, 2006).
P-TEFb is a protein kinase composed of
CDK9 as its catalytic subunit and Cyclin
T1 as a regulatory subunit. Tat binds
directly to Cyclin T1 and the Tat/P-TEFb
complex and then binds to the structured
TAR RNA element that forms within the
first 65 nucleotides of nascent viral
RNA (see Figure 1). After being recruited
to RNAP II by this unusual mechanism,
the CDK9 component of P-TEFb hyper-
phosphorylates the carboxy-terminal do-
main (CTD) of the large subunit of RNAP
II and also phosphorylates the negative
factors that limit elongation. These phos-
phorylation events convert RNAP II into180 Cell Host & Microbe 7, March 18, 2010 ªan enzyme that is efficient in transcribing
the entire proviral genome.
The publication from Pagans and col-
leagues (Pagans et al., 2010) presents
convincing data that show that recruit-
ment of the Tat/P-TEFb complex to TAR
RNA is enhanced by a lysine methyltrans-
ferase named Set7/9-KMT7. Set7/
9-KMT7 binds directly to Tat in vitro and
can be coimmunoprecipitated with the
Tat/P-TEFb complex from cellular ex-
tracts, and the Set7/9-KMT7/Tat/P-TEFb
complex has enhanced binding to TAR
RNA in vitro. Additionally, Set7/9-KMT7
monomethylates a conserved lysine at
residue 51 in the Tat RNA-binding do-
main, and this modification appears to
increase Tat transactivation. Interestingly,
Set7/9-KMT7 can also bind by itself
specifically to TAR RNA in vitro. Impor-
tantly, siRNA depletions of Set7/9-KMT7
in primary CD4+ T lymphocytes reduce
HIV-1 replication. Taken together, these
data show that Set7/9-KMT7 stimulates
Tat/P-TEFb binding to TAR RNA and
also methylates Tat in its RNA-binding
domain, and these functions of Set7/
9-KMT7 increase Tat activation and stim-
ulate viral replication.
The methylation of Tat by Set7/9-KMT7
is just one of several posttranslational
modifications that modulate the function
of the viral protein (see Figure 1). Tat
associates with a number of histone ace-
tyltransferases (HATs)—p300 (KAT3B),
hGCN5 (KAT2A), and PCAF (KAT2B)—
and the association with these enzymes
relieves repressive effects of chromatin
on RNAP II transcription of the integrated2010 Elsevier Inc.provirus (Hetzer et al., 2005). PCAF acet-
ylates lysine 28 in the Tat activation
domain, and this appears to enhance
Tat’s interaction with Cyclin T1 in the
P-TEFb complex. These HATs can also
acetylate the Tat RNA-binding domain,
allowing Tat to bind efficiently to the
Brg-1 subunit of the SWI/SNF chromatin-
remodeling complex, further countering
chromatin repression of the provirus
(Mahmoudi et al., 2006). Furthermore,
acetylation of Tat’s RNA-binding domain
is thought to contribute to dissociation of
Tat from TAR RNA. Tat is deacetylated
by SIRT1, which could allow Tat to recycle
to form a new complex with Set7/
9-KMT7, P-TEFb, and TAR RNA (Hetzer
et al., 2005). Tat is also ubiquitylated
by Hdm2, and this stimulates Tat transac-
tivation by an unknown mechanism (Bre`s
et al., 2003). Taken together, these find-
ings indicate that the process of Tat trans-
activation involves an ordered pathway of
interactions with cellular cofactors and
covalent modifications of the viral protein.
The modifications of Tat enhance its
ability to bind P-TEFb, TAR RNA, and
chromatin-modifying enzymes and to be
subsequently released from TAR RNA
to begin another round of transcriptional
activation. Tat activity can also be nega-
tively regulated by methylation of its
RNA-binding domain by PRMT6 and
SETDB1/2, and it is possible that under
some circumstances, this negative regu-
lation is involved in HIV-1 transcriptional
latency (Xie et al., 2007; Van Duyne
et al., 2008).
Because the HIV-1 provirus is preferen-
tially integrated into transcriptionally ac-
tive sites in thehumangenome, thesubnu-
clear localization of integration sites may
have a significant impact on Tat transacti-
vation. Nuclear regions near nuclear pore
complexes, PML nuclear bodies, and
nuclear speckles are especially active for
RNAP II transcription. The active form of
P-TEFb, as indicated by an essential
phosphorylation in the CDK9 T loop, is
concentrated in nuclear speckles (Dow
et al., 2010). It is therefore possible that
Tat transactivation is optimal when sites
of proviral integration can access specific
subnuclear compartments that contain
high local concentrations of P-TEFb and
other cofactors.
The 50 capping and splicing of cellular
mRNAs are coupled to transcriptional
elongation, and the production of HIV-1
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PreviewsRNA is no exception to this. The Tat/
P-TEFb complex stimulates 50 capping
(Chiu et al., 2002), and it will be inter-
esting to determine whether Set7/9-
KMT7 and the lysine 51 methylation of
Tat plays a role in capping. The Tat/
P-TEFb complex also associates with
the splicing factor SKIP during RNAP II
elongation, and this contributes to Tat
transactivation and influences alternative
splicing (Bre`s et al., 2005). It seems likely
that covalent modifications of Tat can
influence these aspects of Tat function.
For cellular mRNAs, RNAP II elongation
is also coupled to 30 end processing
and export of mature mRNA to the cyto-
plasm, and it would not be surprising if
Tat’s effects on elongation and splicing
are also linked to these processes viaadditional cofactors that remain to be
identified.
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In this issue of Cell Host & Microbe, Iwanaga and colleagues (Iwanaga et al., 2010) report on the construction
of plasmids and artificial chromosomes that are stably maintained throughout the Plasmodium life cycle.
These new tools will have multiple applications, from episome-based genetic strategies to studies on
telomere biology and antigenic variation.Since its implementation 15 years ago
(Wu et al., 1995; van Dijk et al., 1995),
the transfection of Plasmodium has revo-
lutionized the molecular analysis of this
protist. So far, transfection has mainly
been used for inactivating or modifying
parasite genes, by capitalizing on the
100% homologous recombination rate of
electroporated DNA in the Plasmodium
genome. In contrast, episomal transfec-
tion has been hampered by the lack of
robust tools. Bacterial plasmids trans-
fected into human (P. falciparum) or
rodent (P. berghei) infecting Plasmodium
replicate but do not segregate evenly
into daughter parasites during mitosis.Since plasmids are rapidly lost and drug
pressure can only be applied to erythro-
cytic stages of the parasite (Figure 1),
episomes have been of little use for inves-
tigating the biology of the parasite stages
that multiply in the mosquito or in the liver.
Moreover, under selective pressure, plas-
mids are present in high copy numbers
(%50) and in concatemeric forms, intro-
ducing an experimental bias in gene
expression or protein localization/func-
tion studies. In this issue, Iwanaga et al.
(2010) report the construction of circular
plasmids containing Plasmodium centro-
meric sequences, as well as a derivative
artificial chromosome containing telo-meric sequences, which are stably main-
tained at low copy numbers throughout
the P. berghei life cycle in the mosquito
and rodent hosts.
Centromeres are the regions of the eu-
karyotic chromosome that ensure sister
chromatid segregation between daughter
cells during mitosis, by binding to spindle
microtubules via the kinetochore nucleo-
protein complex. Sequencing of the
Plasmodium falciparum genome (23 Mb
in 14 chromosomes) identified short and
extremely A/T-rich regions as candidate
centromeres (Bowman et al., 1999; Gard-
ner et al., 2002), which were also found
in rodent-infecting Plasmodium species7, March 18, 2010 ª2010 Elsevier Inc. 181
